Nurix Therapeutics (NRIX) Net Income towards Common Stockholders (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Net Income towards Common Stockholders for 8 consecutive years, with -$89.5 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders fell 106.0% year-over-year to -$89.5 million; the TTM figure through May 2026 stood at -$342.1 million (down 65.02% YoY), while the FY2025 annual figure was -$264.5 million, down 36.62% from the prior year.
• Net Income towards Common Stockholders declined to -$89.5 million in Q2 2026 per NRIX's latest filing, from -$87.9 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$24.3 million in Q2 2023 and bottomed at -$89.5 million in Q2 2026.
• Historically, Net Income towards Common Stockholders has averaged -$53.3 million across 5 years, with a median of -$45.6 million in 2022.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders surged 46.53% — and 2026, when it tumbled 106.0%.
• Nurix Therapeutics' Net Income towards Common Stockholders stood at -$46.7 million in 2022, then advanced by 10.19% to -$42.0 million in 2023, then sank by 39.55% to -$58.5 million in 2024, then tumbled by 33.6% to -$78.2 million in 2025, then declined by 14.46% to -$89.5 million in 2026.
• Business Quant data shows NRIX's Net Income towards Common Stockholders at -$89.5 million in Q2 2026, -$87.9 million in Q1 2026, and -$78.2 million in Q4 2025.